A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma Journal Article
| Authors: | Ronnen, E. A.; Kondagunta, G. V.; Ishill, N.; Sweeney, S. M.; DeLuca, J. K.; Schwartz, L.; Bacik, J.; Motzer, R. J. |
| Article Title: | A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma |
| Abstract: | The aim of this study was to determine the antitumor activity of 17-(Allylamino)-17-demethoxyge-ldanamycin (17-AAG), a heat shock protein 90(hsp90) inhibitor in patients with metastatic papillary renal cell carcinoma (RCC) or metastatic clear cell RCC. Eligible patients were divided into 2 cohorts based on histological subtype: papillary or clear cell RCC. All patients had advanced RCC with measurable disease, a Karnofsky performance status of at least 70, and no evidence of brain metastases. Twelve patients with clear cell RCC and 8 patients with papillary RCC were treated with 17-AAG on this phase II trial. 17-AAG was given intravenously at 220 mg/m2 twice weekly for 2 weeks followed by a week of rest. Cycle length was 21 days. No patient in either cohort achieved a complete or partial response. Toxicities included elevated liver function tests, optic neuritis, dyspnea, fatigue, and gastrointestinal side effects. Six of the 20 patients required dose reduction. At the dose and schedule used in this trial, 17-AAG did not achieve objective response in the treatment of clear cell or papillary renal cell carcinoma patients. © Springer Science + Business Media, LLC 2006. |
| Keywords: | adult; clinical article; treatment response; aged; aged, 80 and over; middle aged; treatment failure; clinical trial; fatigue; advanced cancer; diarrhea; drug dose reduction; antineoplastic agents; cancer patient; phase 2 clinical trial; cohort studies; blood toxicity; gastrointestinal symptom; myalgia; drug administration schedule; qt prolongation; carcinoma, papillary; cohort analysis; antineoplastic activity; renal cell carcinoma; kidney carcinoma; kidney neoplasms; dyspnea; hyperglycemia; lymphocytopenia; lung embolism; carcinoma, renal cell; cardiotoxicity; brain metastasis; muscle weakness; heat shock protein 90 inhibitor; liver function test; papillary carcinoma; infusions, intravenous; 17-aag; benzoquinones; lactams, macrocyclic; papillary; optic neuritis; clear cell; atrioventricular block; 17 allylamino 17 demethoxygeldanamycin |
| Journal Title: | Investigational New Drugs |
| Volume: | 24 |
| Issue: | 6 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 2006-11-01 |
| Start Page: | 543 |
| End Page: | 546 |
| Language: | English |
| DOI: | 10.1007/s10637-006-9208-z |
| PUBMED: | 16832603 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 70" - "Export Date: 4 June 2012" - "CODEN: INNDD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work